Formpipe Life Science Limited - Limited company accounts 18.2
Formpipe Life Science Limited - Limited company accounts 18.2
REGISTERED NUMBER: |
Report of the Director and |
Financial Statements |
for the Year Ended 31 December 2017 |
for |
Formpipe Life Science Limited |
Formpipe Life Science Limited (Registered number: 05797675) |
Contents of the Financial Statements |
for the year ended 31 December 2017 |
Page |
Company Information | 1 |
Report of the Director | 2 |
Report of the Independent Auditors | 3 |
Statement of Comprehensive Income | 5 |
Balance Sheet | 6 |
Statement of Changes in Equity | 7 |
Notes to the Financial Statements | 8 |
Formpipe Life Science Limited |
Company Information |
for the year ended 31 December 2017 |
DIRECTOR: |
SECRETARY: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
AUDITORS: |
Statutory Auditors and |
Chartered Accountants |
Cawley House |
149-155 Canal Street |
Nottingham |
Nottinghamshire |
NG1 7HR |
Formpipe Life Science Limited (Registered number: 05797675) |
Report of the Director |
for the year ended 31 December 2017 |
The director presents his report with the financial statements of the company for the year ended 31 December 2017. |
PRINCIPAL ACTIVITY |
The principal activity of the company in the year under review was that of software supply and |
consultancy. |
DIVIDENDS |
No dividends will be distributed for the year ended 31 December 2017. |
RESEARCH AND DEVELOPMENT |
The company continues to invest in research and development activities. |
DIRECTOR |
STATEMENT OF DIRECTOR'S RESPONSIBILITIES |
The director is responsible for preparing the Report of the Director and the financial statements in |
accordance with applicable law and regulations. |
Company law requires the director to prepare financial statements for each financial year. Under that law |
the director has elected to prepare the financial statements in accordance with United Kingdom Generally |
Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company |
law the director must not approve the financial statements unless he is satisfied that they give a true and |
fair view of the state of affairs of the company and of the profit or loss of the company for that period. In |
preparing these financial statements, the director is required to: |
- | select suitable accounting policies and then apply them consistently; |
- | make judgements and accounting estimates that are reasonable and prudent; |
- | state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; |
- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
The director is responsible for keeping adequate accounting records that are sufficient to show and |
explain the company's transactions and disclose with reasonable accuracy at any time the financial |
position of the company and enable him to ensure that the financial statements comply with the |
Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for |
taking reasonable steps for the prevention and detection of fraud and other irregularities. |
STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS |
So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the |
Companies Act 2006) of which the company's auditors are unaware, and he has taken all the steps that |
he ought to have taken as a director in order to make himself aware of any relevant audit information |
and to establish that the company's auditors are aware of that information. |
AUDITORS |
The auditors, Clayton & Brewill, will be proposed for re-appointment at the forthcoming Annual General |
Meeting. |
ON BEHALF OF THE BOARD: |
Report of the Independent Auditors to the Members of |
Formpipe Life Science Limited |
Opinion |
We have audited the financial statements of Formpipe Life Science Limited (the 'company') for the year |
ended 31 December 2017 which comprise the Statement of Comprehensive Income, Balance Sheet, |
Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant |
accounting policies. The financial reporting framework that has been applied in their preparation is |
applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 |
'Reduced Disclosure Framework' (United Kingdom Generally Accepted Accounting Practice). |
In our opinion the financial statements: |
- | give a true and fair view of the state of the company's affairs as at 31 December 2017 and of its loss for the year then ended; |
- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
- | have been prepared in accordance with the requirements of the Companies Act 2006. |
Basis for opinion |
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and |
applicable law. Our responsibilities under those standards are further described in the Auditors' |
responsibilities for the audit of the financial statements section of our report. We are independent of the |
company in accordance with the ethical requirements that are relevant to our audit of the financial |
statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical |
responsibilities in accordance with these requirements. We believe that the audit evidence we have |
obtained is sufficient and appropriate to provide a basis for our opinion. |
Conclusions relating to going concern |
We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require |
us to report to you where: |
- | the director's use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or |
- | the director has not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue. |
Other information |
The director is responsible for the other information. The other information comprises the information in |
the Report of the Director, but does not include the financial statements and our Report of the Auditors |
thereon. |
Our opinion on the financial statements does not cover the other information and we do not express any |
form of assurance conclusion thereon. |
In connection with our audit of the financial statements, our responsibility is to read the other information |
and, in doing so, consider whether the other information is materially inconsistent with the financial |
statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, |
based on the work we have performed, we conclude that there is a material misstatement of this other |
information, we are required to report that fact. We have nothing to report in this regard. |
Opinion on other matters prescribed by the Companies Act 2006 |
In our opinion, based on the work undertaken in the course of the audit: |
- | the information given in the Report of the Director for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
- | the Report of the Director has been prepared in accordance with applicable legal requirements. |
Matters on which we are required to report by exception |
In the light of the knowledge and understanding of the company and its environment obtained in the |
course of the audit, we have not identified material misstatements in the Report of the Director. |
We have nothing to report in respect of the following matters where the Companies Act 2006 requires us |
to report to you if, in our opinion: |
- | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or |
- | the financial statements are not in agreement with the accounting records and returns; or |
- | certain disclosures of director's remuneration specified by law are not made; or |
- | we have not received all the information and explanations we require for our audit. |
Report of the Independent Auditors to the Members of |
Formpipe Life Science Limited |
Responsibilities of director |
As explained more fully in the Statement of Director's Responsibilities set out on page two, the director is |
responsible for the preparation of the financial statements and for being satisfied that they give a true |
and fair view, and for such internal control as the director determines necessary to enable the |
preparation of financial statements that are free from material misstatement, whether due to fraud or |
error. |
In preparing the financial statements, the director is responsible for assessing the company's ability to |
continue as a going concern, disclosing, as applicable, matters related to going concern and using the |
going concern basis of accounting unless the director either intends to liquidate the company or to cease |
operations, or has no realistic alternative but to do so. |
Auditors' responsibilities for the audit of the financial statements |
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are |
free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that |
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an |
audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. |
Misstatements can arise from fraud or error and are considered material if, individually or in the |
aggregate, they could reasonably be expected to influence the economic decisions of users taken on the |
basis of these financial statements. |
A further description of our responsibilities for the audit of the financial statements is located on the |
Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms |
part of our Report of the Auditors. |
Use of our report |
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 |
of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's |
members those matters we are required to state to them in a Report of the Auditors and for no other |
purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone |
other than the company and the company's members as a body, for our audit work, for this report, or for |
the opinions we have formed. |
for and on behalf of |
Statutory Auditors and |
Chartered Accountants |
Cawley House |
149-155 Canal Street |
Nottingham |
Nottinghamshire |
NG1 7HR |
Formpipe Life Science Limited (Registered number: 05797675) |
Statement of Comprehensive Income |
for the year ended 31 December 2017 |
2017 | 2016 |
Notes | £ | £ | £ | £ |
TURNOVER |
Cost of sales |
GROSS LOSS | ( |
) | ( |
) |
Distribution costs | ( |
) |
Administrative expenses |
325,288 | 493,018 |
(334,741 | ) | (499,955 | ) |
Other operating income |
OPERATING LOSS | ( |
) | ( |
) |
Income from shares in group undertakings |
Interest receivable and similar income |
- | 33,195 |
(333,495 | ) | (464,619 | ) |
Amounts written off investments | 4 | - | 31,111 |
(333,495 | ) | (495,730 | ) |
Interest payable and similar expenses | 5 |
LOSS BEFORE TAXATION | 6 | ( |
) | ( |
) |
Tax on loss | 8 |
LOSS FOR THE FINANCIAL YEAR | ( |
) | ( |
) |
OTHER COMPREHENSIVE INCOME | - | - |
TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
( |
) |
( |
) |
Formpipe Life Science Limited (Registered number: 05797675) |
Balance Sheet |
31 December 2017 |
2017 | 2016 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Intangible assets | 9 |
Tangible assets | 10 |
CURRENT ASSETS |
Stocks | 11 |
Debtors | 12 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 13 |
NET CURRENT LIABILITIES | ( |
) | ( |
) |
TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
( |
) |
CAPITAL AND RESERVES |
Called up share capital | 15 |
Share premium | 16 |
Retained earnings | 16 | ( |
) | ( |
) |
SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
The financial statements were approved by the director on |
Formpipe Life Science Limited (Registered number: 05797675) |
Statement of Changes in Equity |
for the year ended 31 December 2017 |
Called up |
share | Retained | Share | Total |
capital | earnings | premium | equity |
£ | £ | £ | £ |
Balance at 1 January 2016 | ( |
) | ( |
) |
Changes in equity |
Total comprehensive income | - | ( |
) | - | ( |
) |
Balance at 31 December 2016 | ( |
) | ( |
) |
Changes in equity |
Total comprehensive income | - | ( |
) | - | ( |
) |
Balance at 31 December 2017 | ( |
) | ( |
) |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements |
for the year ended 31 December 2017 |
1. | STATUTORY INFORMATION |
Formpipe Life Science Limited is a private company, limited by shares, registered in England and |
Wales. The company's registered number and registered office can be found on the Company |
Information page. |
2. | ACCOUNTING POLICIES |
Basis of preparation |
These financial statements have been prepared in accordance with Financial Reporting Standard |
101 "Reduced Disclosure Framework" and the Companies Act 2006. The financial statements have |
been prepared under the historical cost convention. |
At 31 December 2017 the company has net current liabilities of £1,282,758 (2016: £1,014,011) |
and net liabilities of £993,306 (2016: 624,059). The accounts have been prepared on a going |
concern basis due to the continued financial support from the parent company. |
The company has taken advantage of the following disclosure exemptions in preparing these |
financial statements, as permitted by FRS 101 "Reduced Disclosure Framework": |
• | the requirements of paragraphs 45(b) and 46 to 52 of IFRS 2 Share-based Payment; |
• | the requirements of paragraphs 62, B64(d), B64(e), B64(g), B64(h), B64(j) to B64(m), B64(n)(ii), B64(o)(ii), B64(p), B64(q)(ii), B66 and B67 of IFRS 3 Business Combinations; |
• | the requirements of paragraph 33(c) of IFRS 5 Non Current Assets Held for Sale and Discontinued Operations; |
• | the requirements of IFRS 7 Financial Instruments: Disclosures; |
• | the requirements of paragraphs 91 to 99 of IFRS 13 Fair Value Measurement; |
• | the requirement in paragraph 38 of IAS 1 Presentation of Financial Statements to present comparative information in respect of: |
- | paragraph 79(a)(iv) of IAS 1; |
- | paragraph 73(e) of IAS 16 Property, Plant and Equipment; |
- | paragraph 118(e) of IAS 38 Intangible Assets; |
- | paragraphs 76 and 79(d) of IAS 40 Investment Property; and |
- | paragraph 50 of IAS 41 Agriculture; |
• | the requirements of paragraphs 10(d), 10)(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D and 111 of IAS 1 Presentation of Financial Statements; |
• | the requirements of paragraphs 134 to 136 of IAS 1 Presentation of Financial Statements; |
• | the requirements of IAS 7 Statement of Cash Flows; |
• | the requirements of paragraphs 30 and 31 of IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors; |
• | the requirements of paragraphs 17 and 18A of IAS 24 Related Party Disclosures; |
• | the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group; |
• | the requirements of paragraphs 134(d) to 134(f) and 135(c) to 135(e) of IAS 36 Impairments of Assets. |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements - continued |
for the year ended 31 December 2017 |
2. | ACCOUNTING POLICIES - continued |
Development costs |
Development costs that are directly attributable to development and testing of identifiable and |
unique software products under the companies control , are recognised as an intangible asset |
when the following criteria are met. |
- Its is technically feasible to complete the software so it is available for use. |
- The company intends to complete the software and to use or sell it |
- Conditions are present to use or sell the software |
- It can be demonstrated how the software will generate probable future economic benefits |
- Adequate terminological, financial, and other resources are available to complete development |
and to use or sell the software |
- The expenses directly attributable to the software, during its development can be reliably |
measured. |
Directly attributable expenses that are capitalised as part of the software development include staff |
costs and an reasonable proportion of the indirect cost. Other development costs that do not meet |
these criteria are charged as they arise. |
Development costs for software recognised as an asset are depreciated over its estimated useful |
life, which does not exceed five years. |
Tangible fixed assets |
Fixtures and fittings | - |
Computer equipment | - |
Stocks |
Stocks are valued at the lower of cost and net realisable value, after making due allowance for |
obsolete and slow moving items. |
Taxation |
Current taxes are based on the results shown in the financial statements and are calculated |
according to local tax rules, using tax rates enacted or substantially enacted by the balance sheet |
date. |
Foreign currencies |
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange |
ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at |
the rate of exchange ruling at the date of transaction. Exchange differences are taken into account |
in arriving at the operating result. |
Hire purchase and leasing commitments |
Rentals paid under operating leases are charged to the profit or loss on a straight line basis over |
the period of the lease. |
Employee benefit costs |
The company operates a defined contribution pension scheme. Contributions payable to the |
company's pension scheme are charged to the income statement in the period to which they |
relate. |
3. | EMPLOYEES AND DIRECTORS |
2017 | 2016 |
£ | £ |
Wages and salaries | 488,152 | 451,737 |
Social security costs |
Other pension costs |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements - continued |
for the year ended 31 December 2017 |
3. | EMPLOYEES AND DIRECTORS - continued |
The average number of employees during the year was as follows: |
2017 | 2016 |
Admin salaries | 11 | 11 |
2017 | 2016 |
£ | £ |
Director's remuneration |
4. | AMOUNTS WRITTEN OFF INVESTMENTS |
2017 | 2016 |
£ | £ |
Write off investments | - | 31,111 |
5. | INTEREST PAYABLE AND SIMILAR EXPENSES |
2017 | 2016 |
£ | £ |
Intercompany loan interest | 35,752 | 25,814 |
Loan |
6. | LOSS BEFORE TAXATION |
The loss before taxation is stated after charging/(crediting): |
2017 | 2016 |
£ | £ |
Cost of inventories recognised as expense |
Other operating leases |
Depreciation - owned assets |
(Profit)/loss on disposal of fixed assets | ( |
) |
Development costs amortisation | 55,199 | 44,411 |
Foreign exchange differences |
7. | AUDITORS' REMUNERATION |
2017 | 2016 |
£ | £ |
Fees payable to the company's auditors for the audit of the company's financial statements |
8. | TAXATION |
Analysis of tax expense |
No liability to UK corporation tax arose for the year ended 31 December 2017 nor for the year |
ended 31 December 2016. |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements - continued |
for the year ended 31 December 2017 |
8. | TAXATION - continued |
Factors affecting the tax expense |
The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The |
difference is explained below: |
2017 | 2016 |
£ | £ |
Loss before income tax | ( |
) | ( |
) |
Loss multiplied by the standard rate of corporation tax in the UK of |
(71,080 |
) |
(104,763 |
) |
Effects of: |
Losses carried forward | 79,821 | 126,721 |
Development costs | (16,478 | ) | (32,400 | ) |
(Profit)/Loss on disposal of assets | (2,764 | ) | 301 |
Depreciation charge in excess of capital allowances | 10,501 | 10,141 |
Tax expense |
A deferred tax asset of £101,180 (2016: £224,522) in respect of trading losses of £532,526 |
(2016: £1,181,693) has not been recognised due to uncertainty over future profits against which |
to offset. |
Previous tax losses of £635,690 were surrendered to a fellow UK subsidiary during the year. |
9. | INTANGIBLE FIXED ASSETS |
Development |
costs |
£ |
COST |
At 1 January 2017 |
Additions |
Disposals | ( |
) |
At 31 December 2017 |
AMORTISATION |
At 1 January 2017 |
Amortisation for year |
Eliminated on disposal | ( |
) |
At 31 December 2017 |
NET BOOK VALUE |
At 31 December 2017 |
At 31 December 2016 |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements - continued |
for the year ended 31 December 2017 |
10. | TANGIBLE FIXED ASSETS |
Fixtures |
and | Computer |
fittings | equipment | Totals |
£ | £ | £ |
COST |
At 1 January 2017 |
Additions |
At 31 December 2017 |
DEPRECIATION |
At 1 January 2017 |
Charge for year |
At 31 December 2017 |
NET BOOK VALUE |
At 31 December 2017 |
At 31 December 2016 |
11. | STOCKS |
2017 | 2016 |
£ | £ |
Finished goods |
12. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2017 | 2016 |
£ | £ |
Trade debtors |
Amounts owed by group undertakings |
Prepayments and accrued income |
13. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2017 | 2016 |
£ | £ |
Trade creditors |
Amounts owed to group undertakings |
Social security and other taxes |
VAT | 10,751 | 5,437 |
Other creditors |
Accrued expenses |
14. | LEASING AGREEMENTS |
Minimum lease payments under non-cancellable operating leases fall due as follows: |
2017 | 2016 |
£ | £ |
Within one year |
Between one and five years |
Formpipe Life Science Limited (Registered number: 05797675) |
Notes to the Financial Statements - continued |
for the year ended 31 December 2017 |
15. | CALLED UP SHARE CAPITAL |
Allotted and issued: |
Number: | Class: | Nominal | 2017 | 2016 |
value: | £ | £ |
Ordinary | £1 | 13,143 | 13,143 |
16. | RESERVES |
Retained | Share |
earnings | premium | Totals |
£ | £ | £ |
At 1 January 2017 | ( |
) | (637,202 | ) |
Deficit for the year | ( |
) | ( |
) |
At 31 December 2017 | ( |
) | (1,006,449 | ) |
17. | PENSION COMMITMENTS |
The company operates a contributory pension scheme. It is a defined contribution scheme and |
contributions are charged in the profit and loss account as they accrue. The charge for the period |
was £37,231 (2016: £37,780). |
18. | ULTIMATE PARENT COMPANY |
Formpipe Software AB (incorporated in Sweden ) is regarded by the director as being the |
company's ultimate parent company. |
19. | ULTIMATE CONTROLLING PARTY |